Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the pharmacokinetics (how drugs are absorbed in
the body, how they are distributed within the body and how they are removed from the body
over time) of ceftobiprole after a single 250-mg intravenous (IV) infusion (given directly
into the vein) for 2 hours, before and after dialysis to patients with end-stage renal
disease (ESRD) requiring hemodialysis or healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Basilea Pharmaceutica
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.